Erratum: Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

Background: The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails. Objective: To further assess how patients with a positive initial response to infliximab respond to 1 year of continuous infliximab treatment. Methods: A retrospective analysis of patients with moderate-to-severe plaque and nail psoriasis who initiated and continued infliximab treatment up to week 46 was conducted. Results: Among all nail psoriasis patients receiving 1 year of infliximab (n = 186), 74.6 and 54.1% achieved at least 75 or 90% improvement in the Psoriasis Area and Severity Index (PASI) at week 50. These PASI-75 (n = 138) and PASI-90 (n = 100) responders had respective mean improvements from baseline to week 50 of 93.6 and 97.3% for the PASI, 90.6 and 94.1% for the Dermatology Life Quality Index (DLQI) and 78.2 and 80.3% for the Nail Psoriasis Severity Index (NAPSI). Conclusions: Infliximab treatment for 1 year produced sustained improvement in PASI, DLQI and NAPSI scores.背景：EXPRESS研究证实了英夫利昔单抗（infliximab）在累及皮肤与指甲的银屑病治疗中的初步疗效。目的：进一步评估初始治疗应答阳性的患者接受为期1年的持续英夫利昔单抗治疗后的反应情况。方法：本研究对起始并持续接受英夫利昔单抗治疗至第46周的中重度斑块状银屑病及指甲银屑病患者开展了回顾性分析。结果：在接受1年英夫利昔单抗治疗的所有指甲银屑病患者（n=186）中，分别有74.6%与54.1%的患者在第50周时达到银屑病面积与严重性指数（Psoriasis Area and Severity Index, PASI）至少75%或90%的改善。上述达到PASI-75（n=138）与PASI-90（n=100）应答的患者，从基线至第50周的平均改善率分别为：PASI指标93.6%与97.3%，皮肤病生活质量指数（Dermatology Life Quality Index, DLQI）90.6%与94.1%，指甲银屑病严重性指数（Nail Psoriasis Severity Index, NAPSI）78.2%与80.3%。结论：为期1年的英夫利昔单抗治疗可使PASI、DLQI及NAPSI评分获得持续改善。